1
|
Bliss-Moreau E, Costa VD, Baxter MG. A pragmatic reevaluation of the efficacy of nonhuman primate optogenetics for psychiatry. OXFORD OPEN NEUROSCIENCE 2022; 1:kvac006. [PMID: 38596709 PMCID: PMC10939311 DOI: 10.1093/oons/kvac006] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/18/2021] [Revised: 03/03/2022] [Accepted: 03/08/2022] [Indexed: 04/11/2024]
Abstract
Translational neuroscience is committed to generating discoveries in the laboratory that ultimately can improve human lives. Optogenetics has received considerable attention because of its demonstrated promise in rodent brains to manipulate cells and circuits. In a recent report, Tremblay et al. [28] introduce an open resource detailing optogenetic studies of the nonhuman primate (NHP) brain and make robust claims about the translatability of the technology. We propose that their quantitative (e.g. a 91% success rate) and theoretical claims are questionable because the data were analyzed at a level relevant to the rodent but not NHP brain. Injections were clustered within a few monkeys in a few studies in a few brain regions, and their definitions of success were not clearly relevant to human neuropsychiatric disease. A reanalysis of the data with a modified definition of success that included a behavioral and biological effect revealed a 62.5% success rate that was lower when considering only strong outcomes (53.1%). This calls into question the current efficacy of optogenetic techniques in the NHP brain and suggests that we are a long way from being able to leverage them in 'the service of patients with neurological or psychiatric conditions' as the Tremblay report claims.
Collapse
Affiliation(s)
- Eliza Bliss-Moreau
- Department of Psychology, University of California Davis,
CA 95616, USA
- California National Primate Research Center, University of California Davis, CA 95616, USA
| | - Vincent D Costa
- Department of Behavioral Neuroscience, Oregon Health Sciences University, OR 97239, USA
- Oregon National Primate Research Center, Oregon Health Sciences University, OR 97239, USA
| | - Mark G Baxter
- Nash Family Department of Neuroscience, Icahn School of Medicine at Mount Sinai, NY 10029-5674, USA
| |
Collapse
|
2
|
Zhu MH, Jogdand AH, Jang J, Nagella SC, Das B, Milosevic MM, Yan R, Antic SD. Evoked Cortical Depolarizations Before and After the Amyloid Plaque Accumulation: Voltage Imaging Study. J Alzheimers Dis 2022; 88:1443-1458. [PMID: 35811528 PMCID: PMC10493004 DOI: 10.3233/jad-220249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
BACKGROUND In Alzheimer's disease (AD), synaptic dysfunction is thought to occur many years before the onset of cognitive decline. OBJECTIVE Detecting synaptic dysfunctions at the earliest stage of AD would be desirable in both clinic and research settings. METHODS Population voltage imaging allows monitoring of synaptic depolarizations, to which calcium imaging is relatively blind. We developed an AD mouse model (APPswe/PS1dE9 background) expressing a genetically-encoded voltage indicator (GEVI) in the neocortex. GEVI was restricted to the excitatory pyramidal neurons (unlike the voltage-sensitive dyes). RESULTS Expression of GEVI did not disrupt AD model formation of amyloid plaques. GEVI expression was stable in both AD model mice and Control (healthy) littermates (CTRL) over 247 days postnatal. Brain slices were stimulated in layer 2/3. From the evoked voltage waveforms, we extracted several parameters for comparison AD versus CTRL. Some parameters (e.g., temporal summation, refractoriness, and peak latency) were weak predictors, while other parameters (e.g., signal amplitude, attenuation with distance, and duration (half-width) of the evoked transients) were stronger predictors of the AD condition. Around postnatal age 150 days (P150) and especially at P200, synaptically-evoked voltage signals in brain slices were weaker in the AD groups versus the age- and sex-matched CTRL groups, suggesting an AD-mediated synaptic weakening that coincides with the accumulation of plaques. However, at the youngest ages examined, P40 and P80, the AD groups showed differentially stronger signals, suggesting "hyperexcitability" prior to the formation of plaques. CONCLUSION Our results indicate bidirectional alterations in cortical physiology in AD model mice; occurring both prior (P40-80), and after (P150-200) the amyloid deposition.
Collapse
Affiliation(s)
- Mei Hong Zhu
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| | - Aditi H Jogdand
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| | - Jinyoung Jang
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| | - Sai C Nagella
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| | - Brati Das
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| | - Milena M Milosevic
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| | - Riqiang Yan
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| | - Srdjan D Antic
- Department of Neuroscience, UConn Health, School of Medicine, Farmington, CT, USA
| |
Collapse
|
3
|
Masneuf S, Imbach LL, Büchele F, Colacicco G, Penner M, Moreira CG, Ineichen C, Jahanshahi A, Temel Y, Baumann CR, Noain D. Altered sleep intensity upon DBS to hypothalamic sleep-wake centers in rats. Transl Neurosci 2021; 12:611-625. [PMID: 35070444 PMCID: PMC8729228 DOI: 10.1515/tnsci-2020-0202] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/24/2021] [Revised: 11/04/2021] [Accepted: 11/22/2021] [Indexed: 11/15/2022] Open
Abstract
Deep brain stimulation (DBS) has been scarcely investigated in the field of sleep research. We hypothesize that DBS onto hypothalamic sleep- and wake-promoting centers will produce significant neuromodulatory effects and potentially become a therapeutic strategy for patients suffering severe, drug-refractory sleep–wake disturbances. We aimed to investigate whether continuous electrical high-frequency DBS, such as that often implemented in clinical practice, in the ventrolateral preoptic nucleus (VLPO) or the perifornical area of the posterior lateral hypothalamus (PeFLH), significantly modulates sleep–wake characteristics and behavior. We implanted healthy rats with electroencephalographic/electromyographic electrodes and recorded vigilance states in parallel to bilateral bipolar stimulation of VLPO and PeFLH at 125 Hz and 90 µA over 24 h to test the modulating effects of DBS on sleep–wake proportions, stability and spectral power in relation to the baseline. We unexpectedly found that VLPO DBS at 125 Hz deepens slow-wave sleep (SWS) as measured by increased delta power, while sleep proportions and fragmentation remain unaffected. Thus, the intensity, but not the amount of sleep or its stability, is modulated. Similarly, the proportion and stability of vigilance states remained altogether unaltered upon PeFLH DBS but, in contrast to VLPO, 125 Hz stimulation unexpectedly weakened SWS, as evidenced by reduced delta power. This study provides novel insights into non-acute functional outputs of major sleep–wake centers in the rat brain in response to electrical high-frequency stimulation, a paradigm frequently used in human DBS. In the conditions assayed, while exerting no major effects on the sleep–wake architecture, hypothalamic high-frequency stimulation arises as a provocative sleep intensity-modulating approach.
Collapse
Affiliation(s)
- Sophie Masneuf
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Lukas L Imbach
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Fabian Büchele
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | | | - Marco Penner
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Carlos G Moreira
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Christian Ineichen
- Preclinical Laboratory for Translational Research into Affective Disorders, Department of Psychiatry, DPPP, Psychiatric Hospital, University of Zurich, Zurich, Switzerland
| | - Ali Jahanshahi
- Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Yasin Temel
- Department of Neurosurgery, Maastricht University Medical Center, Maastricht, The Netherlands
| | - Christian R Baumann
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
| | - Daniela Noain
- Department of Neurology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.,Neuroscience Center Zurich (ZNZ), University of Zurich, Zurich, Switzerland.,Center of Competence Sleep & Health, University of Zurich, Zurich, Switzerland
| |
Collapse
|